European Association for Cancer Research

Novosanis supports the European Association for Cancer Research (EACR), the largest member association for cancer research in Europe. Our partnership allows us to learn about the latest research in the field, as well as communicate our work with the scientific community and members of the association.

To learn more about our URODETECT project, which looks at urine in breast and prostate cancer, visit - https://novosanis.com/urodetect

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.